Cannabinoids could help manage spasticity in motor neuron disease

A very similar drug already exists as a trailed, tested and approved pharmaceutical; if fact has been in on the register for decades…

Sativex (nabiximols) is the first cannabis-based medicine to be licensed in the UK. The drug can prescribed for the treatment for MS-related spasticity when a person has shown inadequate response to other symptomatic treatments or found their side effects intolerable. Sativex can be used in addition to a person's current anti-spasticity medication.